Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5437-5446

  Lin, Yvonne G ^a   Immaneni, Anand ^b   Merritt, William M ^a   Mangala, Lingegowda S ^a   Kim, Seung Wook ^a   Shahzad, Mian M K ^a,b   Tsang, Yvonne T M ^a   Armaiz Pena, Guillermo N ^a,b   Lu, Chunhua ^a   Kamat, Aparna A ^a   Han, Liz Y ^a   Spannuth, Whitneya ^a   Nick, Alpa M ^a   Landen Jr , Charles N ^a   Wong, Kwong K ^a   Gray, Michael J ^a   Coleman, Robert L ^a   Bodurka, Diane C ^a   Brinkley, William R ^b   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DOCETAXEL; PROTEIN SERINE THREONINE KINASE; ANTINEOPLASTIC AGENT; AURORA KINASE; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL CYCLE REGULATION; CELL PROLIFERATION; CHEMOSENSITIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; ANIMAL; APOPTOSIS; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; OVARY TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; OVARIAN NEOPLASMS; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 53049109358     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4922     Document Type: Article

References (43)

1. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7.
2. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006;12:6869-75.
3. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22:451-64.
4. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev 2004;4:927-36.
5. Matthews N, Visintin C, Hartzoulakis B, Jarvis A, Selwood DL. Aurora A and B kinases as targets for cancer: will they be selective for tumors? Exp Rev Anticancer Ther 2006;6:109-20.
6. Landen CN, Jr., Lin YG, Immaneni A, et al. Overex-pression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 2007;13:4098-104.
7. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-13 in ovarian cancer. Clin Cancer Res 2000;6:1833-9.
8. Hu W, Kavanagh JJ, Deaver M, et al. Frequent over-expression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res 2005;15:49-57.
9. Dicioccio RA, Song H, Waterfall C, et al. STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1589-94.
10. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003;3:51-62.
11. Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 2006;119:2304-12.
12. Sun C, Chan F, Briassouli P, Linardopoulos S. Aurora kinase inhibition downregulates NF-κB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun 2007;352:220-5.
13. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161:281-94.
14. Girdler F, Gascoigne KE, Eyers PA, et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006;119:3664-75.
15. Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol CancerTher 2006;5:2905-13.
16. Jemal A,SiegelR, Ward E, Murray T, Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57: 43-66.
17. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993;53:891-8.
18. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985;45:3668-76.
19. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;90: 447-54.
20. Han LY, Landen CN, Trevino JG, et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006;66:8633-9.
21. Lin YG, Kunnumakkara AB, Nair A, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin Cancer Res 2007;13:3423-30.
22. Landen CN, Jr., Lu C, Han LY, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006;98:1558-70.
23. Landen CN, Jr., Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-8.
24. Halder J, Kamat AA, Landen CN, Jr.,et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24.
25. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44.
26. Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol 2004;27:14-8.
27. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-91.
28. Kamat AA, Kim TJ, Landen CN, Jr., et al. Metronomic chemotherapy enhances the efficacy of anti- vascular therapy in ovarian cancer. Cancer Res 2007;67:281-8.
29. Wong KK, Chang YM, Tsang YT, et al. Expression analysis of juvenile pilocytic astrocytomas byoligonucleotide microarray reveals two potential subgroups. Cancer Res 2005;65:76-84.
30. Li C, Wong WH. Model-based analysis of oligonu- cleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98:31-6.
31. TusherVG,Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
32. Gizatullin F,YaoY, KungV, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66:7668-77.
33. Garcia JM, Cata JP, Dougherty PM, Smith RG. Ghrelin prevents cisplatin-induced mechanical hyper- algesia and cachexia. Endocrinology 2008;149: 455-60.
34. HiroseA, Sato E,Fujii H, Sun B, Nishioka H, Aruoma OI. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol 2007;222:152-8.
35. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev 2005;5:42-50.
36. Kiat LS, Hui KM, Gopalan G. Aurora-A kinase interacting protein (AIP), a novel negative regulator of human Aurora-A kinase. J Biol Chem 2002;277:45558-65.
37. Manfredi MG, Ecsedy JA, Meetze KA, et al. Anti- tumor activity of MLN8054, an orally active small- molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA2007;104:4106-11.
38. Fidler IJ, Kim SJ, Langley RR. The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 2007;101:927-36.
39. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006;97: 813-20.
40. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005; 65:2899-905.
41. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004;64:3550-8.
42. Roberts D, Schick J, Conway S, et al. Identification ofgenes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 2005;92:1149-58.
43. Giles FJ, CortesJ, JonesD, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with theT315I BCR-ABL mutation. Blood 2007;109:500-2.